Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 428 across all filing types
Latest filing 2024-02-03 Regulatory Filings
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an official communication to the National Stock Exchange of India Limited informing about a scheduled conference call to discuss the company's Q3FY24 earnings. It includes details about the date, time, and participation of management team members. The document does not contain actual financial results or detailed financial statements but serves as an invitation and notification of the upcoming earnings call. According to the classification rules, such a document is best classified as a Call Transcript (CT) if it contained the full transcript, but since this is only an invitation notice, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call, not the call transcript itself or the earnings release. The document length is under 5,000 characters and it is an announcement rather than the report or transcript itself.
2024-02-03 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding the publication of unaudited financial results for the quarter and nine months ended December 31, 2023. It mentions Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which mandates the publication of financial results in newspapers. The document includes copies of newspaper publications of these unaudited financial results. The content is primarily an announcement of the publication of financial results, not the full financial report itself. The document length is about 14,918 characters, but the content is focused on the announcement and newspaper publication of the unaudited financial results, not the detailed financial statements or analysis. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of a report rather than the report itself. Hence, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not contain the full report or detailed financial data.
2024-02-03 English
Financial Result Updates
Regulatory Filings
2024-02-02 English
Board Meeting — VAISHALI PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 02-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for t…
Regulatory Filings
2024-01-25 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice from Vaishali Pharma Limited to the National Stock Exchange of India about an upcoming Board Meeting scheduled for February 2, 2024. The purpose of the meeting includes considering and approving the standalone unaudited financial results for the quarter and nine months ended December 31, 2023. The document also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document is short (2050 characters) and serves as an intimation or announcement of a board meeting rather than the financial results themselves. It does not contain any financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Interim Report or Earnings Release.
2024-01-25 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a Compliance Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2023. It is a letter addressed to the National Stock Exchange of India Limited, confirming compliance related to shareholding and dematerialisation status. The document is short (2317 characters) and primarily serves as a certification or attestation rather than containing financial data or detailed report content. It does not contain financial statements or substantive financial analysis. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a compliance certificate and not a full financial or management report.
2024-01-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.